Showing 9991-10000 of 15195 results for "reverse type I diabetes".
- Florida's New Law on C-Sections: A Potential Model Amid Safety Concernshttps://reachmd.com/news/floridas-new-law-on-c-sections-a-potential-model-amid-safety-concerns/2471069/Quick Summary Florida has enacted a law permitting cesarean sections in clinics, which could serve as a model for other states. While the law aims to improve maternity care access and reduce costs, it faces opposition due to safety concerns and the involvement of pr
- Unveiling the Molecular Basis of Eosinophilic Esophagitishttps://reachmd.com/news/unveiling-the-molecular-basis-of-eosinophilic-esophagitis/2471090/What's New A recent study led by Children's Hospital of Philadelphia offers groundbreaking insights into the molecular interactions that underlie eosinophilic esophagitis, a persistent food allergy affecting many children. The study has identified a specific
- Emerging Photopharmaceutical Advancements in Psoriasis Treatmenthttps://reachmd.com/news/emerging-photopharmaceutical-advancements-in-psoriasis-treatment/2471101/Quick Summary A study published in the Journal of the American Chemical Society highlights the efficacy of a new photoswitchable drug, MRS7787, in treating psoriasis. MRS7787 is activated by blue light and acts on the A3 adenosine receptor, providing targeted immune
- Study: Herbal Approach Counteracts Cardio Side Effects of PsO in Ratshttps://reachmd.com/news/Study-Herbal-Approach-Counteracts-Cardio-Side-Effects-PsO-Rats/2471102/An herbal therapy approach demonstrated cardioprotective effects on rats with psoriasis in a study recently published in Molecular and Cellular Biochemistry. The study, titled “Galium verum L. extract mitigates cardiovascular events in psoriasis rats,” utilized 5% imiquim
- Pacific Northwest Practice Hiringhttps://reachmd.com/news/Pacific-Northwest-Practice-Hiring/2471098/Clear Choice Dermatology announced it is seeking a board-certified dermatologist to work in its locations in Portland, Oregon, or Salem, Oregon. Clear Choice has 11 locations throughout Oregon and Washington. Owner and Chief Medical Officer Collin Blattner, DO, FAAD, is a member of Pra
- Phase 1 Study Begins for New Systemic for CPUOhttps://reachmd.com/news/Phase-1-Study-Begins-New-Systemic-CPUO/2471095/The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic co
- Study: Quality, Reliability of TikTok Videos on Spironolactone Is Suspecthttps://reachmd.com/news/Study-Quality-Reliability-TikTok-Videos-Spironolactone-Suspect/2471094/The quality and reliability of information on TikTok regarding spironolactone for acne treatment is concerning, according to a new study by George Washington University researchers. An analysis of the top 50 TikTok videos under the hashtag #spironolactone, which had received 108 million vi
- GW Earns Skin Smart Campus Recognitionhttps://reachmd.com/news/GW-Earns-Skin-Smart-Campus-Recognition/2471093/The National Council on Skin Cancer Prevention recognized George Washington University as a Skin Smart Campus for its ongoing commitment to fostering a safe and healthy learning environment, with a focus on skin cancer prevention and UV safety, the university announced. The Skin Smart Camp
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://reachmd.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w
- Baricitinib: A New Hope for Lichen Planus Reliefhttps://reachmd.com/news/baricitinib-a-new-hope-for-lichen-planus-relief/2471067/Quick Summary Researchers from the Mayo Clinic have identified baricitinib as a promising treatment for lichen planus, leading to significant improvements. The trial showed an 83% improvement in symptom responsiveness within 16 weeks. Understanding Lichen Pl